The first ctDNA predictive biomarker/companion diagnostic to enter clinical use involved mutational analysis of EGFR for the identification of patients with NSCLC that were likely to benefit from EGFR tyrosine kinase inhibitors (TKIs) [30,31,32]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.